Neurologic autoimmunity and immune checkpoint inhibitors
Autoantibody profiles and outcomes
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received February 25, 2020
- Accepted in final form May 27, 2020
- First Published August 13, 2020.
Article Versions
- Previous version (August 13, 2020 - 12:45).
- You are viewing the most recent version of this article.
Author Disclosures
- Elia Sechi, MD,
- Svetomir N. Markovic, MD,
- Andrew McKeon, MD,
- Divyanshu Dubey, MD,
- Teerin Liewluck, MD,
- Vanda A. Lennon, MD, PhD,
- A. Sebastian Lopez-Chiriboga, MD,
- Christopher J. Klein, MD,
- Michelle Mauermann, MD,
- Sean J. Pittock, MD,
- Eoin P. Flanagan, MD and
- Anastasia Zekeridou, MD, PhD
- Elia Sechi, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Svetomir N. Markovic, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Andrew McKeon, MD,
NONE
NONE
NONE
I am a member of the editorial board of Neurology: Neuroimmunology and Neuroinflammation
Patent applications pending: Septin 5, Septin 7, GFAP, PDE10A, Kelch-11 and MAP1B as markers of neurological autoimmunity and paraneoplastic disorders
NONE
NONE
NONE
NONE
NONE
NONE
Euroimmun Alexion
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Divyanshu Dubey, MD,
Dr. Divyanshu Dubey has attended UCB Advisory Board Meeting in Lyon, France on September 23, 2019. All compensation for consulting activities is paid directly to Mayo Clinic.
Dr. Dubey has consulted for UCB and Astellas pharmaceuticals. All compensation for consulting activities is paid directly to Mayo Clinic.
Dr. Dubey has been a speaker at American Academy of Neurology Annual conference. All compensation for speaking activities is paid directly to Mayo Clinic.
Dr. Dubey is on the editorial board of Journal of Clinical Medicine.
Dr. Dubey has patent pending for Klech like 11 protein as a marker of neurological autoimmunity.
NONE
NONE
NONE
NONE
NONE
NONE
Dr. Dubey has received research support from Grifols pharmaceuticals.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Teerin Liewluck, MD,
NONE
NONE
NONE
Muscle and Nerve; Editorial Board; since 2016-no compensation Frontiers in Neurology; Editorial Board and Guest Associate Editor; since 2018-no compensation
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Department of Neurology Discretionary Fund, Mayo Clinic- unrelated to this manuscript
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Vanda A. Lennon, MD, PhD,
NONE
NONE
NONE
NONE
Vanda Lennon receives royalties 1) from RSR/Kronus for sale of aquaporin-4 autoantibody testing kits and 2) for commercial aquaporin-4 autoantibody testing performed outside Mayo Clinic.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NIH R01 NS110949, Co-Principal Investigator, 2020-2024
NONE
MN Partnership for Biotechnology and Medical Genomics, grant # ML2017, Chapter 89, Art, section #4 (e) Sub-award # P007067701
NONE
1) RSR/Kronus for sale of aquaporin-4 autoantibody testing kits. 2) Non-Mayo sites performing "home brew" diagnostic testing for aquaporin-4 autoantibody.
Dr. Lennon has a potential financial interest in the technologies listed below: "Aquaporin-4 as an aid for cancer diagnosis".
NONE
NONE
NONE
- A. Sebastian Lopez-Chiriboga, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Christopher J. Klein, MD,
I sit on the CMTA therapeutics board, CMTA is a non- profit organization.
NONE
I received honorarium for an educational talk in an Ackea sponsored symposium at the Peripheral Nerve Society meeting in June 2019.
Neuromuscular editorial board for Neurology
NONE
NONE
NONE
NONE
NONE
I attended an Polyneuropathy Advisory meeting organized by Pfizer who paid trip expense. I did not receive personal compensation.
NONE
NONE
NONE
Mayo Clinic Research Grant
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Michelle Mauermann, MD,
NONE
NONE
NONE
Mayo Clinic Proceedings, Section Editor, 2016 and onwards
NONE
Autonomic Neurology, Oxford
NONE
NONE
NONE
NONE
NONE
Ionis Pharmaceuticals, Inc. Alnylam Pharmaceuticals
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Sean J. Pittock, MD,
Alexion Pharmaceutical Advisory Board Medimmune/Viele Bio Advisory Board UCB pharmaceuticals Astellas
NONE
NONE
NONE
Dr. Pittock has a patent Patent# 8,889,102 (Application#12-678350) - Neuromyelitis Optica Autoantibodies as a Marker for Neoplasia issued, and a patent Patent# 9,891,219B2 (Application#12-573942) - Methods for Treating Neuromyelitis Optica (NMO) by Administration of Eculizumab to an individual that is Aquaporin-4 (AQP4)-IgG Autoantibody positive issued. Dr Pittock has a patent pending for GFAP, Septin-5, Kelch11 and MAP1B autoantibodies as biomarkers of neurological autoimmunity.
NONE
NONE
Dr. Pittock has provided consultation to Alexion Pharmaceuticals and Medimmune but has received no personal fees or personal compensation for these consulting activities. All compensation for consulting activities is paid directly to Mayo Clinic.
NONE
No activity to report. I am a salaried employee of Mayo Clinic and salary is fixed specialty dependent and not impacted by test volume or laboratory income.
NONE
Dr Pittock has received research funding from Grifols, Medimmune/Viela Bio, Alexion and AEA (Autoimmune Encephalitis Associations).
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Eoin P. Flanagan, MD and
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
I am currently a site primary investigator in a randomized clinical trial on Medi551 in neuromyelitis optica spectrum disorder run by Medimmune. I receive compensation for time related to that activity.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Anastasia Zekeridou, MD, PhD
NONE
NONE
NONE
NONE
Patent for PDE10A-IgG as a biomarker of neurological autoimmunity
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Departments of Neurology (E.S., A.M., D.D., T.L., V.A.L., C.J.K., M.M., S.J.P., E.P.F., A.Z.), Oncology (S.N.M.), Laboratory Medicine and Pathology (A.M., D.D., V.A.L., S.J.P., E.P.F., A.Z.), and Immunology (V.A.L.), Mayo Clinic, Rochester, MN; and Department of Neurology (A.S.L.-C.), Mayo Clinic, Jacksonville, FL.
- Correspondence
Dr. Zekeridou zekeridou.anastasia{at}mayo.edu
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Cutaneous α-Synuclein Signatures in Patients With Multiple System Atrophy and Parkinson Disease
Dr. Rizwan S. Akhtar and Dr. Sarah Brooker
► Watch
Related Articles
- No related articles found.
Alert Me
Recommended articles
-
Article
Phosphodiesterase 10A IgGA novel biomarker of paraneoplastic neurologic autoimmunityAnastasia Zekeridou, Thomas Kryzer, Yong Guo et al.Neurology, July 17, 2019 -
Article
Immunoadsorption therapy in autoimmune encephalitidesMüjgan Dogan Onugoren, Kristin S. Golombeck, Corinna Bien et al.Neurology - Neuroimmunology Neuroinflammation, February 26, 2016 -
Article
Updated Diagnostic Criteria for Paraneoplastic Neurologic SyndromesFrancesc Graus, Alberto Vogrig, Sergio Muñiz-Castrillo et al.Neurology: Neuroimmunology & Neuroinflammation, May 18, 2021 -
Article
Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancerMehdi Touat, Thierry Maisonobe, Samuel Knauss et al.Neurology, August 08, 2018